LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

Accueil・Liste d'Actions・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Ouvert

SecteurSoins de santé

21.45 -0.23

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

21.45

Max

21.45

Chiffres clés
By Trading Economics
Revenu	-1.6M -21M
Ventes	14M 54M
Marge bénéficiaire	-39.611
Employés	178
EBITDA	-3.8M -23M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	-3.62% downside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	1B 2.2B
Ouverture précédente	21.68
Clôture précédente	21.45

Sentiment de l'Actualité

By Acuity

50%

136 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

6.26 / 7.47 Support & Résistance

Day One Biopharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 mai 2026, 23:53 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Acquisitions, Fusions, Rachats

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Acquisitions, Fusions, Rachats

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Acquisitions, Fusions, Rachats

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Acquisitions, Fusions, Rachats

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Acquisitions, Fusions, Rachats

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparaison

Variation de prix

Day One Biopharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

-3.62% baisse

Prévisions sur 12 Mois

Moyen 20.75 USD -3.62%

Haut 21.5 USD

Bas 17 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

6.26 / 7.47Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

136 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.